

# Glucocorticoid receptor polymorphisms do not affect the therapy efficiency in adult, Hungarian patients with 21-hydroxylase deficiency

Klára Koncz<sup>1,2</sup>, Abigél Farkas<sup>1</sup>, Marton Doleschall<sup>3</sup>, Nikolette Szucs<sup>1</sup>, Miklos Toth<sup>1</sup>, Peter Igaz<sup>1</sup>, Karoly Racz<sup>1</sup>, Attila Patocs<sup>1,2</sup>

<sup>1</sup> 2<sup>nd</sup> Department of Medicine, Semmelweis University, Budapest, Hungary

<sup>2</sup> "Lendület" Hereditary Endocrine Tumors Research Group, Hungarian Academy of Sciences – Semmelweis University, Budapest, Hungary

<sup>3</sup> Molecular Medicine Research Group, Hungarian Academy of Sciences – Semmelweis University, Budapest, Hungary

## Background

Congenital adrenal hyperplasia (CAH) is an autosomal recessive inherited disorder caused by 21-hydroxylase deficiency in 95% of all cases. Two main clinical subtypes: the classical (manifested after birth or in early newborn period) and the late onset (LO) phenotype (manifested commonly during puberty) can be distinguished. The lifelong glucocorticoid (GC) supplementation is essential in therapy of these patients. Response and need for GC therapy is individual and partly genetically determined.


## Objective

- Our aim was to study the effect of three well-known polymorphisms (SNPs) (BclII, N363S, A3669G) of the GR gene on therapy, clinical and laboratory parameters in adult Hungarian patients with 21-hydroxylase deficiency.
- To examine whether the copy number (CN) of the CYP21A2 gene influences the therapy in our patients.


## Patients and Methods

The diagnosis of 21-hydroxylase deficiency was based on clinical, laboratory and molecular genetic tests including the identification of the most common *CYP21A2* gene mutations and determination of the allelic copy number (CN) of the *CYP21A2* gene.

In 93 patients (54 classical: 34 salt wasting + 20 simple virilising and 39 late-onset, age: 28,8 13,7 years) with 21-hydroxylase deficiency the BclII and N363S polymorphisms were measured using allele-specific PCR, the A3669G polymorphism and the CN variations were detected by real-time qPCR. Allele frequencies of GR polymorphisms were compared to a Hungarian, control population (n=160). Association between GR SNPs and clinical, hormone laboratory and GC supplementation dosage was studied. For statistical analysis were used ANOVA, Student t test, Fisher's exact test and Chi-square test.



Walker B Eur J Endocrinol November 1, 2007 vol. 157 no. 5 545-559



Merke P et al. Ann Intern Med. 2002;136(4):320-334. doi:10.7326/0003-4819-136-4-200202190-00012




## Results


Allelic frequency of the GR polymorphisms did not differ from those observed in control population and did not associate with clinical, laboratory parameters or dosage of the GC supplementation. The copy number of the *CYP21A2* in both groups of patients significantly negatively correlated with GC therapy ( $p=0,03$ ).

## Discussion


The GR polymorphisms-related sensitivity against glucocorticoids is not a major factor in determination of the dose of glucocorticoid supplementation in Hungarian, adult patients with CAH. The *CYP21A2* copy number measurement is a rapid, cheap and sensitive method for prediction the GC need in patients with 21-hydroxylase deficiency.




Parameters (n=93)	Classical CAH (n=54)				Late Onset CAH (n=39)		
	BclII	N363S	A3669G	CN of CYP21A2 (1 vs. 2)	BclII	A3669G	CN of CYP21A2 (1 vs. 2)
P values of the statistical analysis (significance level $p < 0,05$ )							
17-OHP (ng/dL)	0,232	0,250	0,706	0,594	0,918	0,52	0,967
ACTH (pg/mL)	0,241	0,873	0,943	0,889	0,998	0,902	0,594
Androstendion (ng/dL)	0,802	0,796	0,954	0,856	0,568	0,595	0,136
DHEA (ng/dL)	0,956	0,195	0,676	0,199	0,546	0,976	0,017
DHEAS (µg/dL)	0,758	0,681	0,434	0,175	0,014	0,636	0,829
Cortisol (µg/dL)	0,459	0,871	0,422	0,887	0,685	0,209	0,452
Aldosterone (ng/dL)	0,745	0,757	0,273	0,293	0,858	0,133	0,391
Testosterone (ng/dL)	0,323	0,935	0,171	0,799	0,415	0,175	0,278
Renin aktivitás (ng/mL/óra)	0,537	0,501	0,919	0,999	0,772	0,498	0,117
Hydrocortison-ekvivalens/mg	0,503	0,672	0,454	0,028*	0,786	0,246	0,024*
Therapy							
Hydrocortison-ekvivalens-dose/weight	0,642	0,660	0,382	0,02*	0,917	0,591	0,03*
Radiology							
CT morphology of the adrenal glands	0,291	0,546	0,402	0,063	0,803	-	0,054
Antropometry							
BMI	0,817	0,864	0,942	0,894	0,440	0,335	0,531



Classical CAH



Late onset CAH



The authors acknowledge the financial support from Hungarian Research Found (OTKA PD100648) and from National Development Agency (KTIA\_AIK-2-2012-0010)